Unexpected hyperglycemia may be an early symptom of infection. Use with caution in diabetes mellitus. Risk of increased serum osmolality and possible intracerebral hemorrhage in very low birth weight infants due to excessive or rapid dextrose administration. Parenteral dextrose solutions contain aluminum which may reach toxic levels with prolonged administration, particularly in impaired renal function (CNS and bone toxicity), including in premature neonates. Avoid using oral forms in unconscious patients. Rebound hypoglycemia may be associated with abrupt withdrawal. Hypertonic solutions (>10%) may cause thrombosis if infused via peripheral veins. Risk of hyperglycemia and/or hyperosmolar syndrome (e.g. dehydration, hypovolemia, mental confusion, loss of consciousness) with rapid administration, especially in chronic uremia and known carbohydrate intolerance. Possible fluid and/or solute overload resulting in dilution of serum electrolytes, overhydration, congested conditions, or pulmonary edema. Infusion site and other reactions (e.g. fever, infection at the injection site, venous thrombosis, hypervolemia, extravasation, phlebitis extending from injection site) might occur. Hypertonic dextrose injections may cause local pain or venous irritation or damage. Possible hypokalemia and hypophosphatemia after prolonged use of concentrated dextrose solutions. Risk of glucose intolerance and hyperglycemia in pediatric patients, especially in low-birthweight infants and neonates. Risk of increased serum osmolality and possible intracerebral hemorrhage with excessive or rapid administration in low-birthweight infants.